{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Karron RA"],"funding":["NICHD NIH HHS","NIAID NIH HHS"],"pagination":["594-603"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7924568"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["203(5)"],"pubmed_abstract":["<b>Rationale:</b> Active immunization is needed to protect infants and young children against respiratory syncytial virus (RSV). Rationally designed live-attenuated RSV vaccines are in clinical development.<b>Objectives:</b> Develop preliminary estimates of vaccine efficacy, assess durability of antibody responses to vaccination and \"booster\" responses after natural RSV infection, and determine sample sizes needed for more precise estimates of vaccine efficacy.<b>Methods:</b> We analyzed data from seven phase 1 trials of live-attenuated RSV vaccines in 6- to 24-month-old children (<i>n</i> = 239).<b>Measurements and Main Results:</b> The five vaccine regimens that induced neutralizing antibody responses in ≥80% of vaccinees (defined <i>post hoc</i> as \"more promising\") protected against RS"],"journal":["American journal of respiratory and critical care medicine"],"pubmed_title":["Live-attenuated Vaccines Prevent Respiratory Syncytial Virus-associated Illness in Young Children."],"pmcid":["PMC7924568"],"funding_grant_id":["UM1 AI068632","UM1 AI106716","UM1 AI069536","HHSN275201800001I","UM1 AI068616","HHSN275201800001C","P30 AI064518","U01 AI069536"],"pubmed_authors":["Cunningham CK","Aziz M","Karron RA","Libous J","Perlowski C","Woods S","Collins PL","Wanionek K","Spector SA","Atwell JE","McFarland EJ","Muresan P","Yogev R","Buchholz UJ"],"additional_accession":[]},"is_claimable":false,"name":"Live-attenuated Vaccines Prevent Respiratory Syncytial Virus-associated Illness in Young Children.","description":"<b>Rationale:</b> Active immunization is needed to protect infants and young children against respiratory syncytial virus (RSV). Rationally designed live-attenuated RSV vaccines are in clinical development.<b>Objectives:</b> Develop preliminary estimates of vaccine efficacy, assess durability of antibody responses to vaccination and \"booster\" responses after natural RSV infection, and determine sample sizes needed for more precise estimates of vaccine efficacy.<b>Methods:</b> We analyzed data from seven phase 1 trials of live-attenuated RSV vaccines in 6- to 24-month-old children (<i>n</i> = 239).<b>Measurements and Main Results:</b> The five vaccine regimens that induced neutralizing antibody responses in ≥80% of vaccinees (defined <i>post hoc</i> as \"more promising\") protected against RS","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Mar","modification":"2026-05-31T05:01:25.059Z","creation":"2025-02-19T01:53:33.913Z"},"accession":"S-EPMC7924568","cross_references":{"pubmed":["32871092"],"doi":["10.1164/rccm.202005-1660OC","10.1164/rccm.202005-1660oc"]}}